Inactive Instrument

News Anpath Group, Inc. Other OTC

Equities

US03634J3041

End-of-day quote Other OTC Other stock markets
- ^USD	-

05-03	Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	CI
03-20	QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	05-02	CI
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER	04-16	AQ
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals	02-07	AQ
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee	11-14	AQ
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	11-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding	28/09/23	CI
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data	16/08/23	AQ
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)	23/06/23	AQ
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	14/06/23	AQ
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	14/06/23	CI
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center	23/05/23	AQ
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	23/05/23	CI
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®	16/05/23	AQ
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®	26/04/23	AQ
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	26/04/23	CI
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	11/04/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Anpath Group, Inc. Other OTC

Equities

US03634J3041

Summary

Filters